Skip to main content
. 2024 Nov 12;6(24):6079–6095. doi: 10.1039/d4na00660g

MicroRNA in drug resistance with potential targets in breast cancer.

MicroRNA Expression levels Resistant drug Target Function Reference
miR-221 Upregulated Tamoxifen P27 kip1 Enhances proliferation and invasion 56
miR-155 Upregulated Doxorubicin FOXO Promotes proliferation and reduces apoptosis 57
miR-30b Upregulated Trastuzumab CCNE2 Induces the apoptosis pathway 58
miR-26a Upregulated Trastuzumab CCNE2 Induces the apoptosis pathway 58
miR-21 Upregulated Trastuzumab PTEN, PDCD4 Cell survival, apoptosis, resistance to systemic therapy 59
miR-107 Downregulated Paclitaxel E2F1 Promotes apoptosis 60
miR-7 Downregulate Trastuzumab EGFR Induces cell proliferation and metastasis 61
miR-128 Upregulated Letrozole TGBR1 Growth inhibitory effect of TGFβ 62
miR-214 Downregulated Tamoxifen UCP2 Inhibition of autophagy 63
miR-159 Upregulated Doxorubicin Wnt Promotes apoptosis 64
miR-16 Upregulated Doxorubicin Bcl-2 Induces tumor cell apoptosis 65
miR-298 Upregulated Doxorubicin P-gp Alters MDR modulation 66
miR-302b Downregulated Cisplatin E2F1 Inhibit cell cycle progression 67
Let-7a Upregulated Paclitaxel ABCB10 Promotes invasion and autophagy 68
miR-375 Downregulated Trastuzumab IGF1R Reverse EMT 69
miR-125 Downregulated Trastuzumab ERBB2, ERBB3 Reverse EMT 70
miR-200c Downregulated Trastuzumab ZNF217, ZEB1 Inhibit TGF-β signaling 71
miR-27b Downregulated Tamoxifen HMGB3 Promotes apoptosis 72
miR-124 Upregulated Doxorubicin STAT3 Resists the mechanism of cancer stem cells 73
miR-199b Downregulated Trastuzumab HER2 Inhibits ERK1/2 and AKT pathways 74